CN102046180A - 用于免疫治疗的组合物和方法 - Google Patents

用于免疫治疗的组合物和方法 Download PDF

Info

Publication number
CN102046180A
CN102046180A CN2009801205538A CN200980120553A CN102046180A CN 102046180 A CN102046180 A CN 102046180A CN 2009801205538 A CN2009801205538 A CN 2009801205538A CN 200980120553 A CN200980120553 A CN 200980120553A CN 102046180 A CN102046180 A CN 102046180A
Authority
CN
China
Prior art keywords
cell
benzaldehyde
formula
compositions
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801205538A
Other languages
English (en)
Chinese (zh)
Inventor
J·E·布朗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognate3 LLC
Original Assignee
Cognate3 LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognate3 LLC filed Critical Cognate3 LLC
Publication of CN102046180A publication Critical patent/CN102046180A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN2009801205538A 2008-04-03 2009-04-03 用于免疫治疗的组合物和方法 Pending CN102046180A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4221008P 2008-04-03 2008-04-03
US61/042,210 2008-04-03
PCT/US2009/002134 WO2009145841A1 (en) 2008-04-03 2009-04-03 Compositions and methods for immunotherapy

Publications (1)

Publication Number Publication Date
CN102046180A true CN102046180A (zh) 2011-05-04

Family

ID=41267359

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801205538A Pending CN102046180A (zh) 2008-04-03 2009-04-03 用于免疫治疗的组合物和方法

Country Status (12)

Country Link
US (5) US20090281047A1 (https=)
EP (1) EP2271350A4 (https=)
JP (1) JP2011516478A (https=)
CN (1) CN102046180A (https=)
AU (1) AU2009251848A1 (https=)
CA (1) CA2757437A1 (https=)
IL (1) IL208445A0 (https=)
MX (1) MX339451B (https=)
NZ (1) NZ588668A (https=)
RU (1) RU2010144744A (https=)
WO (1) WO2009145841A1 (https=)
ZA (1) ZA201007830B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789154A (zh) * 2016-08-03 2019-05-21 珠海贝海生物技术有限公司 福沙吡坦和阿瑞吡坦的制剂

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
WO2010080345A1 (en) * 2008-12-19 2010-07-15 Graceway Pharmaceuticals, Llc Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
EA025993B1 (ru) 2009-07-13 2017-02-28 Медисис Фармасьютикал Корпорейшн Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
WO2011156119A1 (en) * 2010-06-07 2011-12-15 Abraxis Bioscience, Llc Combination therapy methods for treating proliferative diseases
US20130171279A1 (en) * 2012-01-04 2013-07-04 Physicianrx, Llc Composition for Reducing Side- and After-Effects of Cancer Treatment
CN103156951A (zh) * 2013-04-11 2013-06-19 太仓市胜舟生物技术有限公司 一种治疗b细胞淋巴瘤的组合药物
US20160296555A1 (en) * 2013-12-20 2016-10-13 Ramiro Moises VERGARA CAMPILLO Combination of pyridoxine, folic acid and magnesium ions for treating cancer
CA3013768A1 (en) * 2016-02-04 2017-08-10 Stem Cell Theranostics, Inc. Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
US20200360408A1 (en) * 2017-08-07 2020-11-19 Joe Emest BROWN Compositions And Methods For Inducing Apoptosis In Anaerobic Cells And Related Clinical Methods For Treating Cancer And Pathogenic Infections
WO2022200833A1 (en) * 2021-03-25 2022-09-29 2B-Shvat Ltd. Benzaldehyde extracted from rosales as foodstuff preservative, animal-feed additive, and for treatment of the covid-19 virus
JP7018531B1 (ja) 2021-04-30 2022-02-10 潤 齋藤 Ａｘｌ阻害剤
IL315231A (en) * 2022-02-24 2024-10-01 Shmuel Robinov Methods of using benzaldehyde preparations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882314A (en) * 1985-12-02 1989-11-21 Rikagaku Kenkyusho A composition and method of treating selected malignant conditions
WO2000048610A1 (en) * 1999-02-19 2000-08-24 Norsk Hydro Asa Chemical compounds
US6407071B1 (en) * 1998-06-04 2002-06-18 Co-Enzyme Technology Ltd. Method and composition for treating malignant cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882314A (en) * 1985-12-02 1989-11-21 Rikagaku Kenkyusho A composition and method of treating selected malignant conditions
US6407071B1 (en) * 1998-06-04 2002-06-18 Co-Enzyme Technology Ltd. Method and composition for treating malignant cells
WO2000048610A1 (en) * 1999-02-19 2000-08-24 Norsk Hydro Asa Chemical compounds
WO2000048609A1 (en) * 1999-02-19 2000-08-24 Norsk Hydro Asa Chemical compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109789154A (zh) * 2016-08-03 2019-05-21 珠海贝海生物技术有限公司 福沙吡坦和阿瑞吡坦的制剂
CN109789154B (zh) * 2016-08-03 2021-05-14 珠海贝海生物技术有限公司 福沙吡坦和阿瑞吡坦的制剂

Also Published As

Publication number Publication date
NZ588668A (en) 2013-01-25
ZA201007830B (en) 2011-07-27
US20110311477A1 (en) 2011-12-22
AU2009251848A1 (en) 2009-12-03
JP2011516478A (ja) 2011-05-26
US20090281047A1 (en) 2009-11-12
MX339451B (es) 2016-05-27
US20120251490A1 (en) 2012-10-04
EP2271350A1 (en) 2011-01-12
WO2009145841A1 (en) 2009-12-03
IL208445A0 (en) 2010-12-30
RU2010144744A (ru) 2012-05-10
US20110311476A1 (en) 2011-12-22
MX2010010866A (es) 2011-02-24
US20110311478A1 (en) 2011-12-22
EP2271350A4 (en) 2011-05-18
CA2757437A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
CN102046180A (zh) 用于免疫治疗的组合物和方法
US8501243B2 (en) Targeting cancer therapy combination
JP2018513130A (ja) Ｈｓｐ９０阻害ペプチド結合体及びその腫瘍治療における応用
CN112704679A (zh) 含高三尖杉酯碱的药物组合物及其应用
US9901602B2 (en) Ejaculum of animals as medicinal material and uses thereof in medicaments for treatment of diseases such as tumors, depression, etc
CN102441168A (zh) 含芹菜素及芹菜素类衍生物和Bcl-2抑制剂的药物组合物及其在制备治疗癌症的药物中的应用
CN109674789B (zh) 羧胺三唑与谷氨酸摄取与代谢抑制剂在抗肿瘤中的用途
EP3964217A1 (en) Use of compound or pharmaceutically acceptable salt, dimer or trimer thereof in preparation of drug for treating cancer
US20160008388A1 (en) Compositions and methods for immunotherapy
WO2014047782A1 (zh) 含有白藜芦醇及白藜芦醇类衍生物和Bcl-2抑制剂的药物组合物及其应用
CN102688489A (zh) 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
TWI358295B (en) Epothilone derivatives and radiation
CN116549455A (zh) PLK4抑制剂Centrinone在制备治疗包虫病药物中的应用
US20070207198A1 (en) Use Of N-Acety1-D-Glucosamine In The Manufacture Of Medicaments For Anti-Tumors And Anti-Metastasis
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
CN111514290B (zh) 一种葫芦素组合物及其用途
CN111032035A (zh) 用于替司他赛和卡培他滨的给药方案
US20200253998A1 (en) Compositions And Methods For Immunotherapy
CN107921134B (zh) 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物
CN101574340B (zh) 杜鹃素及其盐在制备抗肿瘤药物中的应用
TW201100072A (en) A pharmaceutical composition for treating septic shock
WO2023239842A1 (en) Beta carbolines as topical anti-inflammatory agents for application to mucous membranes
HK40059774A (en) Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in the preparation of medicament for treating cancer
CN102626426B (zh) 抗肿瘤复方茯苓素制剂及其制备方法
CN120678788A (zh) 唾液酸乳糖穿透血脑屏障向促进老年人大脑健康的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20110504